UBS lowered the firm’s price target on Incyte (INCY) to $94 from $104 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte appoints Stein as Chief Medical Officer, Issa as EVP
- Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
- Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
- Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
- Incyte downgraded to Hold from Buy at Jefferies